Financials

v3.7.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Current Assets    
Cash $ 436,086 $ 182,561
Trade accounts receivable, net 519,624 444,743
Other receivables 2,250
Product deposit 74,043
Inventory, net 127,448 160,270
Total Current Assets 1,157,201 789,824
Current Liabilities    
Accounts payable and accrued expenses 561,833 752,930
Derivative liabilities 955,014 192,254
Convertible notes payable 100,000
Notes payable, net of discount in 2016 74,043 106,365
Total Current Liabilities 1,590,890 1,151,549
Stockholders' Equity (Deficit)    
Common stock, $0.01 par value; 50,000,000 shares authorized, 40,995,763 and 35,570,157 shares issued, 40,657,963 and 35,245,157 outstanding as of June 30, 2017 and December 31, 2016, respectively 409,957 355,701
Additional paid-in capital 9,532,060 9,070,064
Accumulated (deficit) (10,001,198) (9,693,882)
Equity (59,181) (268,117)
Treasury stock, 337,800 and 325,000 shares, at cost (90,204) (87,053)
Total Immudyne, Inc. Stockholders' (Deficit) (149,385) (355,170)
Non-controlling interest (284,304) (6,555)
Total Stockholders' (Deficit) (433,689) (361,725)
Total Liabilities and Stockholders' (Deficit) $ 1,157,201 $ 789,824

Source

v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Net Sales $ 1,107,418 $ 1,227,247 $ 1,531,880 $ 2,868,275
Cost of Sales 329,246 700,977 532,602 2,038,919
Gross Profit 778,172 526,270 999,278 829,356
Operating expenses        
Compensation and related expenses 243,956 475,056 602,444 715,511
Professional fees 121,952 125,359 221,584 194,674
Marketing expenses 289,070 299,870
General and administrative expenses 348,671 79,487 475,843 177,899
Total operating expenses 1,003,649 679,902 1,599,741 1,088,084
Operating (Loss) (225,477) (153,632) (600,463) (258,728)
Change in fair value of derivative liability 922,022 873,830
Interest (expense) (250) (2,750) (649,607) (5,813)
Net Income (Loss) 696,295 (156,382) (376,240) (264,541)
Net (loss) income attributable to noncontrolling interests (41,194) 43,594 (68,924) (2,516)
Net Income (loss) attributable to Immudyne, Inc. $ 737,489 $ (199,976) $ (307,316) $ (262,025)
Basic income (loss) per share attributable to Immudyne, Inc. $ 0.02 $ (0.01) $ (0.01) $ (0.01)
Diluted income (loss) per share attributable to Immudyne, Inc. $ 0.02 $ (0.01) $ (0.01) $ (0.01)
Average number of common shares outstanding        
Basic 40,849,638 32,338,946 39,224,839 32,174,661
Diluted 47,254,218 32,338,946 39,224,839 32,174,661

Source

v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) attributable to Immudyne, Inc. $ (307,316) $ (262,025)
Net (loss) attributable to noncontrolling interests (68,924) (2,516)
Net (Loss) (376,240) (264,541)
Adjustments to reconcile net (loss) to net cash (used) by operating activities    
Change in fair value of derivative liability (873,830)
Bad debt recovery (44,543)
Amortization of debt discount 81,558
Loss on settlement of notes and other payables 634,325
Stock compensation expense 113,522 118,562
Common stock issued for services 160,833 230,000
Changes in Assets and Liabilities    
Trade accounts receivable (30,338) (296,638)
Other receivables 2,250
Product deposit (74,043)
Inventory 32,822 (118,204)
Accounts payable and accrued expenses (138,885) 254,159
Net cash (used) by operating activities (512,569) (76,662)
CASH FLOWS FROM FINANCING ACTIVITIES    
Investment in subsidiary by noncontrolling interest, net 63,378 79,130
Proceeds from notes payable 309,043
Repayment of convertible note payable (100,000)
Repayment of notes payable (176,420)
Sale of common stock and warrants 673,244
Purchase of treasury stock (3,151)
Net cash provided by financing activities 766,094 79,130
Net increase in cash 253,525 2,468
Cash at beginning of the period 182,561 232,984
Cash at end of the period 436,086 235,452
Supplemental Disclosure of Cash Flow Information    
Cash paid during the period for interest 3,612 5,813
Issuance of company stock for notes and other payables 242,192
Conversion of equity invested in subsidiary to common stock and warrants 272,203
Reclassification of options, warrants and other contracts to derivative liabilities upon issuance $ 1,636,590

Source